Schering takes Resovist to Japan:
This article was originally published in Clinica
Schering has received Japanese market approval for its liver-specific MRI contrast media, Resovist. The product will be marketed by the firm's Japanese subsidiary, Nihon Schering KK. Resovist, which was approved in Europe in 2001, will be available in around ten countries by the end of the year, said Schering. It is used for the detection and characterisation of especially small focal liver lesions, enabling doctors to make a reliable diagnosis at a very early stage, the company added.